Propanc Biopharma, Inc. (PPCB) Income Statement
PPCB FY2026 at a glance
Fiscal year ended June 30, 2026 · U.S. dollarsPPCB revenue and net income
PPCB growth rates
to FY2026| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
PPCB quarterly EPS vs estimates
Propanc Biopharma beat the analyst EPS estimate in 0 of the last 2 quarters. Next report: November 13, 2026.
PPCB income statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $22,702 | — | $21,656 | $17,760 | $5,671 | $28,112 | $2,473 | $2,306 | $2,225 | $2,166 |
| Gross profit | −$22,702 | — | −$21,656 | −$17,760 | −$5,671 | −$28,112 | −$2,473 | −$2,306 | −$2,225 | −$2,166 |
| Research & development | $625,477 | $223,721 | $248,102 | $247,919 | $256,052 | $230,956 | $179,987 | $260,335 | $1.8M | $971,769 |
| Sales, general & admin | $17.6M | $57.1M | $1.3M | $1.5M | $1.7M | $1.6M | $3.3M | $2.4M | $2.1M | $4.8M |
| Total operating expenses | $18.2M | $57.3M | $1.5M | $1.8M | $2.0M | $1.8M | $3.5M | $2.6M | $4.0M | $5.7M |
| Operating income | −$18.2M | −$57.3M | −$1.5M | −$1.8M | −$2.0M | −$1.8M | −$3.5M | −$2.6M | −$4.0M | −$5.7M |
| Interest income | — | $9 | $60 | $36 | $5,613 | $1 | $946 | $31 | $87 | $685 |
| Interest expense | $430,539 | $563,757 | $665,841 | $532,821 | $568,798 | $449,457 | $1.7M | $1.3M | $2.8M | $3.2M |
| Income before taxes | −$18.9M | −$58.9M | −$1.9M | −$2.8M | −$2.7M | −$2.1M | −$4.9M | −$5.9M | −$7.2M | −$8.2M |
| Income taxes | — | — | −$129,132 | −$129,841 | −$54,977 | −$113,000 | −$135,000 | −$115,000 | −$179,000 | −$306,000 |
| Net income | −$18.9M | −$58.9M | −$1.8M | −$2.7M | −$2.7M | −$2.0M | −$4.7M | −$5.8M | −$7.0M | −$7.9M |
| EBITDA | −$18.4M | −$58.3M | −$1.3M | −$2.3M | −$2.1M | −$1.7M | −$3.1M | −$4.6M | −$4.4M | −$5.0M |
| EPS (diluted) | −$5.70 | −$116.47 | −$45.01 | −$0.14 | −$0.06 | −$0.67 | −$4.23 | −$1000000.99 | −$0.66 | −$932.80 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $29,904 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $6,383 | $6,586 | $6,032 | $3,702 | $14,952 | $5,086 | $4,332 | $5,534 | $5,764 | $4,773 | $5,857 | $5,262 |
| Gross profit | −$6,383 | −$6,586 | −$6,032 | −$3,702 | $14,952 | −$5,086 | −$4,332 | −$5,534 | −$5,764 | −$4,773 | −$5,857 | −$5,262 |
| Research & development | $375,655 | $169,660 | $19,961 | $60,201 | $53,522 | $54,097 | $54,388 | $61,714 | $52,390 | $65,448 | $114,022 | $16,242 |
| Sales, general & admin | $3.1M | $6.2M | $3.6M | $4.6M | $3.6M | $53.1M | $158,994 | $229,076 | $207,509 | $360,192 | $324,042 | $395,715 |
| Total operating expenses | $3.5M | $6.4M | $3.7M | $4.7M | $3.6M | $53.1M | $213,382 | $290,790 | $259,899 | $420,867 | $438,064 | $411,957 |
| Operating income | −$3.5M | −$6.4M | −$3.7M | −$4.7M | −$3.6M | −$53.1M | −$213,382 | −$290,790 | −$259,899 | −$420,867 | −$438,000 | −$417,000 |
| Interest income | — | $13 | $37 | $19 | $7 | $1 | $0 | $1 | $0 | $27 | $16 | $17 |
| Interest expense | $27,665 | $38,270 | $58,955 | $305,649 | $254,542 | $104,042 | $118,943 | $86,230 | $90,004 | $133,141 | $264,462 | $178,234 |
| Income before taxes | −$4.6M | −$6.4M | −$3.1M | −$4.8M | −$4.1M | −$54.1M | −$430,183 | −$354,310 | −$358,815 | −$526,975 | −$713,000 | −$351,000 |
| Income taxes | — | — | — | — | — | — | — | — | −$237 | −$275 | −$129,000 | $142,575 |
| Net income | −$4.6M | −$6.4M | −$3.1M | −$4.8M | −$4.1M | −$54.1M | −$430,183 | −$354,310 | −$358,578 | −$526,700 | −$584,000 | −$351,000 |
| EBITDA | −$3.5M | −$6.3M | −$3.0M | −$4.5M | −$3.8M | −$54.0M | −$306,908 | −$262,546 | −$263,047 | −$389,061 | −$443,000 | −$167,738 |
| EPS (diluted) | — | — | — | −$0.39 | −$0.35 | −$12.50 | −$67.65 | −$35.97 | −$44.93 | −$0.01 | −$0.03 | −$0.04 |
| Gross margin | — | — | — | — | 50.0% | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | −12,189.8% | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | −13,615.1% | — | — | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in PPCB's financial statements (latest annual report filed September 25, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
PPCB financial results
Propanc Biopharma reported no revenue in fiscal year 2026 (ended June 30, 2026). It had a net loss of $18.9 million. Diluted earnings per share came to −$5.70.
See the PPCB stock overview for the latest quote and news, or the PPCB chart for price history and technical indicators.
PPCB income statement FAQ
Does Propanc Biopharma have revenue?
Propanc Biopharma reported no revenue for fiscal year 2026, which ended on June 30, 2026.
Is Propanc Biopharma profitable?
No. Propanc Biopharma reported a net loss of $18.9 million in fiscal 2026.
How much does Propanc Biopharma spend on research and development?
Propanc Biopharma spent $0.6 million on research and development in fiscal 2026.
What are Propanc Biopharma's earnings per share?
Propanc Biopharma earned $-5.70 per diluted share in fiscal 2026, compared with $-116.47 a year earlier.
When will Propanc Biopharma report its next earnings?
Propanc Biopharma is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
When does Propanc Biopharma's fiscal year end?
Propanc Biopharma's fiscal year ends in June. The latest annual report covers the year ended June 30, 2026 and was filed on September 25, 2026.